Ultragenyx Pharmaceutical Inc at Goldman Sachs Healthcare Conference Transcript
All right, welcome back, everyone.
Today, we have the pleasure of speaking with Emil Kakis, President and CEO of Ultragenex.
Questions & Answers
And maybe to start, just to level set, you are sitting in front of key Phase 3 Angelman data in the second-half of the year on the potential path to profitability in 2027. So in that context, how is Rare positioned from here in the second-half of the year and then over the next few years? And what are the company's key priorities?
Certainly, we certainly have to be here and be talking with you today.
We started the year off with a difficult problem with missing an OI at Phase III and that was tough.
But we have a lot more than OI in the program, in the company. And so Angelman is the big driver of what people are most interested in. It's the biggest upside product.
We've done a lot of work in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
